|Chemical and physical data|
|Molar mass||320.75086 g/mol|
|3D model (JSmol)|
Tenidap was a COX/5-LOX inhibitor and cytokine-modulating anti-inflammatory drug candidate that was under development by Pfizer as a promising potential treatment for rheumatoid arthritis, but Pfizer halted development after marketing approval was rejected by the FDA in 1996 due to liver and kidney toxicity, which was attributed to metabolites of the drug with a thiophene moiety that caused oxidative damage.
- Wylie, G.; Appelboom, T.; Bolten, W.; Breedveld, F. C.; Feely, J.; Leeming, M. R.; Le Loët, X.; Manthorpe, R.; Marcolongo, R.; Smolen, J. (1995). "A comparative study of tenidap, a cytokine-modulating anti-rheumatic drug, and diclofenac in rheumatoid arthritis: A 24-week analysis of a 1-year clinical trial". British Journal of Rheumatology. 34 (6): 554–563. doi:10.1093/rheumatology/34.6.554. PMID 7543348.
- Staff, American Journal of Nursing. Drug Watch: Tenidap Offers Arthritis Therapy Minus Toxicity AJN 1996 96(1):58
- Pfizer. Sept 27, 1996 Press release: Pfizer To Halt Plans For Commercialization Of Tenidap For Rheumatoid Arthritis
- Hwang SH et al. Rationally designed multitarget agents against inflammation and pain. Curr Med Chem. 2013;20(13):1783-99. PMID 23410172 PMC 4113248